Publication Date:
1986-01-31
Description:
p-Chloromercuriphenylsulfonic acid (PCMS), a sulfhydryl inhibitor, prevented the mycelial-to-yeast transition of the dimorphic fungal pathogen, Histoplasma capsulatum. The effect of PCMS was specific for the mycelial-to-yeast transformation; it had no effect on growth of either the yeast or mycelial forms or on the yeast-to-mycelial transition. The failure of PCMS-treated mycelia to transform to yeast was permanent and irreversible. PCMS-treated mycelia could not infect mice but could stimulate resistance to infection by a pathogenic strain of Histoplasma capsulatum. These results suggest a new general strategy for vaccine development in diseases caused by dimorphic pathogens.〈br /〉〈span class="detail_caption"〉Notes: 〈/span〉Medoff, G -- Sacco, M -- Maresca, B -- Schlessinger, D -- Painter, A -- Kobayashi, G S -- Carratu, L -- AI 07015/AI/NIAID NIH HHS/ -- AI 07172/AI/NIAID NIH HHS/ -- AI 16228/AI/NIAID NIH HHS/ -- New York, N.Y. -- Science. 1986 Jan 31;231(4737):476-9.〈br /〉〈span class="detail_caption"〉Record origin:〈/span〉 〈a href="http://www.ncbi.nlm.nih.gov/pubmed/3001938" target="_blank"〉PubMed〈/a〉
Keywords:
4-Chloromercuribenzenesulfonate/pharmacology
;
Animals
;
Cytochromes/metabolism
;
Energy Metabolism/drug effects
;
Fungal Proteins/biosynthesis
;
Histoplasma/drug effects/pathogenicity/*physiology
;
Histoplasmosis/etiology
;
Kinetics
;
Mice
;
Oxidative Phosphorylation/drug effects
;
Oxygen Consumption/drug effects
Print ISSN:
0036-8075
Electronic ISSN:
1095-9203
Topics:
Biology
,
Chemistry and Pharmacology
,
Computer Science
,
Medicine
,
Natural Sciences in General
,
Physics
Permalink
